Study title: Bruggers-C-S, Greene-D. Dr. C.S. Bruggers, Division of Pediatric Hematology-Oncology, Primary Children's Medical Center, 100 North Medical Drive, Salt Lake City, UT 84113, United States A phase 2 feasibility study of sequential, dose intensive chemotherapy to treat progressive low-grade gliomas in children. Journal of Pediatric Hematology/Oncology {J-PEDIATR-HEMATOL-ONCOL}, 2007, Vol/Iss/Pg. 29/9 (602-607), eISSN: 1536-3678, ISSN: 1077-4114.Bruggers-C-S, Greene-D. Dr. C.S. Bruggers, Division of Pediatric Hematology-Oncology, Primary Children's Medical Center, 100 North Medical Drive, Salt Lake City, UT 84113, United States A phase 2 feasibility study of sequential, dose intensive chemotherapy to treat progressive low-grade gliomas in children. Jour...
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Cardiovascular Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: ENALAPRIL | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |